Related Experiment Video
Updated: Aug 9, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Geminin as a molecular target for the development of new anticancer drugs
1Department of Life Sciences, Meiji University, Kanagawa 214-8571, Japan. yoshida@isc.meiji.ac.jp
Abstract:
The unique biological properties of Geminin, particularly as an inhibitor of DNA replication initiation, have been recognized, and this has prompted a number of investigations into this molecule to explore its potential therapeutic as well as diagnostic usefulness. This review summarizes the possibility of Geminin serving as a new molecular target in the development of new anticancer drugs.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...